Compare RELY & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELY | MLYS |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 2021 | 2023 |
| Metric | RELY | MLYS |
|---|---|---|
| Price | $13.77 | $32.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $26.00 | ★ $47.33 |
| AVG Volume (30 Days) | ★ 2.5M | 1.5M |
| Earning Date | 02-18-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,544,865,000.00 | N/A |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $18.57 | N/A |
| P/E Ratio | $145.89 | ★ N/A |
| Revenue Growth | ★ 31.27 | N/A |
| 52 Week Low | $12.08 | $8.24 |
| 52 Week High | $27.32 | $47.65 |
| Indicator | RELY | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 33.20 |
| Support Level | $13.06 | $31.67 |
| Resistance Level | $13.88 | $33.64 |
| Average True Range (ATR) | 0.41 | 1.67 |
| MACD | 0.00 | -0.23 |
| Stochastic Oscillator | 55.07 | 19.56 |
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.